Norepinephrine Infusion During Cardiopulmonary Bypass

• Status: Recruiting
• Trial end date: 2021-05-01
• Target enrollment: 0
• Participant gender: All

Summary

The primary objective is to test the efficacy and safety of the accuracy of continuous intravenous infusion of norepinephrine during cardiopulmonary bypass (CPB) on the prevention of hyperlactatemia after cardiac surgery.

"Efficacy" would be tested with measurement of the postoperative changes in lactic acid level over time from the baseline value before induction of general anesthesia.

"safety" would be tested with observing the post-cardiotomy need for inotropic and vasopressor support, the incidence of postoperative acute kidney injury (AKI), changes in cardiac troponin level (CnTnI), and signs of ischemic splanchnic injury.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Dammam University
• Treatments: Norepinephrine

Criteria

Inclusion Criteria:

• American Society of Anesthesiologists (ASA) physical status between ІІІ and ІV

• Scheduled for any type of elective cardiac surgery using CPB

• General anesthesia provided in an endotracheally intubated patient.

Exclusion Criteria:

• Decline consent to participate.

• Emergency surgery.

• Ejection fraction (EF%) less than 35%.

• Scheduled for re-do surgery.

• Scheduled for emergency surgery.

• Preoperative ventilator or circulatory support.

• Body mass index (BMI) greater than 40 Kg/m2.

• History of alcohol abuse.

• History of drug abuse.

• Pregnancy.

• Consent for another interventional study during anaesthesia

• No written informed consent.